Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian F Chapin

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
European Urology Oncology|June 16, 2019
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance ImagingMatthew Truong, Janet E Baack Kukreja, Soroush Rais-Bahrami, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
European Urology|August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND TrialAlexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.
European Urology Oncology|June 16, 2019
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance ImagingMatthew Truong, Janet E Baack Kukreja, Soroush Rais-Bahrami, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
European Urology|August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND TrialAlexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Pageof 12